Carregant...
Tipus de document
ArticleVersió
Versió publicadaData de publicació
Tots els drets reservats
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/145337
Ceftobiprole for the treatment of pneumonia
Títol de la revista
Director/Tutor
ISSN de la revista
Títol del volum
Recurs relacionat
Resum
Ceftobiprole is a fifth-generation cephalosporin with potent antimicrobial activity against Gram positive and Gram-negative bacteria. It has been approved in major European countries for the treatment of community-acquired pneumonia (CAP) and hospital-acquired pneumonia (HAP), excluding ventilator-associated pneumonia (VAP). Ceftobiprole is currently in a phase 3 clinical program for registration in the U.S. In 2015, it was designated as an infectious disease product qualified for the treatment of lung and skin infections by the FDA. The efficacy of ceftobiprole in pneumonia has been demonstrated in two-phase III clinical trials conducted in patients with CAP and HAP. The recommended dose in the adult with pneumonia is 500 mg every 8 h infused in 2 h; in case of renal failure, the regimen of administration must be adjusted according to the patient's renal function. It is not necessary to adjust the dose according to gender, age, body weight or liver failure. In case of hyperfiltration, an extension to 4 h infusion of the 500mg TID is required.
Matèries
Matèries (anglès)
Citació
Citació
CILLÓNIZ, Catia, DOMINEDÒ, Cristina, GARCIA VIDAL, Carolina, TORRES MARTÍ, Antoni. Ceftobiprole for the treatment of pneumonia. _Revista Española de Quimioterapia_. 2019. Vol. 32, núm. 3, pàgs. 17-23. [consulta: 21 de gener de 2026]. ISSN: 0214-3429. [Disponible a: https://hdl.handle.net/2445/145337]